MétaCan
Menu
Back to cohort
Record W4292978844 · doi:10.1200/jco.22.00644

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

2022· article· en· W4292978844 on OpenAlexaff
Matthew P. Deek, Kim Van der Eecken, Philip Sutera, Rebecca A. Deek, Valérie Fonteyne, Adrianna A. Mendes, Karel Decaestecker, Ana P. Kiess, Nicolaas Lumen, Ryan Phillips, Aurélie De Bruycker, Mark V. Mishra, Zaker Rana, Jason K. Molitoris, Bieke Lambert, Louke Delrue, Hailun Wang, Kathryn Lowe, Sofie Verbeke, Jo Van Dorpe, Renée Bultijnck, Geert Villeirs, Kathia De Man, Filip Ameye, Daniel Y. Song, Theodore L. DeWeese, Channing J. Paller, Felix Y. Feng, Alexander W. Wyatt, Kenneth J. Pienta, Maximillian Diehn, Søren M. Bentzen, Steven Joniau, Friedl Vanhaverbeke, Gert De Meerleer, Emmanuel S. Antonarakis, Tamara L. Lotan, Alejandro Berlín, Shankar Siva, Piet Ost, Phuoc T. Tran

Bibliographic record

VenueJournal of Clinical Oncology · 2022
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsPrincess Margaret Cancer CentreUniversity of British Columbia
FundersNational Cancer InstituteAstellas PharmaAstraZeneca
KeywordsMedicineHazard ratioInternal medicineOncologyProstate cancerClinical endpointCancerClinical trialConfidence interval

Abstract

fetched live from OpenAlex

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/ 2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.025
metaresearch head score (Gemma)0.017
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.025
Threshold uncertainty score0.134

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0250.017
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.008
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.308
GPT teacher head0.540
Teacher spread0.232 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations243
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicProstate Cancer Treatment and ResearchFrench-language works237,207